Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan for Cardiac Allograft Vasculopathy Mechanism
NCT05373108Phase 4Completed
- Sponsor
- University of California, Los Angeles
- Start
- May 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of macitentan in cardiac allograft vasculopathy (CAV), sponsored by University of California, Los Angeles. Primary endpoint: Nitroglycerin Luminal Dilation Ratio as Proportion of Vasomotor Tone Attributable to Endothelin-1 at 1 week. Started May 2022; status: completed.
02
Drugs
macitentan
03
Conditions
cardiac allograft vasculopathy (CAV)
Beyond the preview
Go deeper on NCT05373108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373108.